Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
DC
First Claim
Patent Images
1. A method of treating sexual dysfunction in a patient in need thereof comprising orally administering one or more unit dose containing about 1 to about 20 mg, up to a maximum total dose of 20 mg per day, of a compound having the structure
2 Assignments
Litigations
6 Petitions
Accused Products
Abstract
The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
31 Citations
12 Claims
-
1. A method of treating sexual dysfunction in a patient in need thereof comprising orally administering one or more unit dose containing about 1 to about 20 mg, up to a maximum total dose of 20 mg per day, of a compound having the structure
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeICOS Corporation (Eli Lilly and Company)
-
Original AssigneeLilly ICOS LLC (Eli Lilly and Company)
-
InventorsWhitaker, John Steven, Pullman, William Ernest
-
Primary Examiner(s)Cook, Rebecca
-
Application NumberUS10/031,556Time in Patent Office1,966 DaysField of Search514/250US Class Current514/250CPC Class CodesA61K 31/00 Medicinal preparations cont...A61K 31/4985 Pyrazines or piperazines or...
